Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer
Status:
Unknown status
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
In recent years, treatment of advanced pancreatic cancer is changing. Currently, there are
several active schedules of chemotherapy that can be used, such as gemcitabine as monotherapy
or in combination with capecitabine or erlotinib, and FOLFIRINOX. Moreover, the development
of biomarker (therapeutic targets) that can predicte response to treatment is a new important
tool to be used in clinical practice to select the best scheme for each patient. Preliminary
studies showed that therapeutic target determination, using tumor tissue collected from
patients, could determine the presence of groups of "chemotherapy responders". Such is the
case of EGFR amplification and/or K-Ras gene status and correlation with response to
erlotinib. Moreover, Thymidilate Synthase, Thimidine Phosphorylase, ERCC-1 and Topoisomerase
I expression by immunohistochemistry in GI tumor samples has been related to resistance or
response to 5FU-capecitabine, oxaliplatin and irinotecan respectively. Based on this data the
investigators designed a phase II clinical trial to evaluate the efficacy of selected
treatment for pancreatic cancer patients based on the determination of therapeutic targets.
The therapeutic target-driven treatment efficacy will be compared to the prospective
treatment of a control group of patients treated at the discretion of the
physician-researcher